Radiographic Contrast Agent
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Radiographic Contrast Agent
Radiographic Contrast Agents are a class of diagnostic drugs designed to enhance the visibility of internal body structures in medical imaging, primarily X-ray based techniques like computed tomography (CT) and fluoroscopy. Their mechanism of action relies on their ability to absorb X-rays more effectively than surrounding tissues due to their high atomic number elements, typically iodine or barium. This differential absorption creates contrast, allowing radiologists to better delineate organs, blood vessels, and pathological lesions that might otherwise be indistinguishable. The first approved radiographic contrast agent, LIPIODOL, an ethiodized oil, was introduced in 1954 by GUERBET for lymphography and later found utility in hepatocellular carcinoma treatment. This marked the beginning of a field that has since evolved significantly with the development of safer and more effective agents.
The field is characterized by continuous innovation aimed at improving patient safety, reducing adverse reactions, and enhancing diagnostic accuracy. Newer generations of contrast agents, such as iohexol (OMNIPAQUE) and iopamidol (ISOVUE), introduced in 1985, represent advancements over earlier formulations. These later agents are typically non-ionic, iodinated compounds that offer lower osmolality and viscosity, leading to better patient tolerance and fewer side effects like nausea, vomiting, and allergic-like reactions. The focus has shifted towards optimizing these agents for specific imaging modalities and patient populations, ensuring they remain indispensable tools in modern diagnostics.
37 FDA-approved Radiographic Contrast Agent drugs, including E-Z-DISK. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Radiographic Contrast Agent Drugs
37 totalRadiographic Contrast Agent drugs have a long history, originating with LIPIODOL, an ethiodized oil introduced by GUERBET in 1954 for lymphography and hepatocellular carcinoma. The evolution of this class saw a significant leap with the introduction of non-ionic, iodinated contrast media in the mid-1980s. Drugs like iohexol (OMNIPAQUE) from GE HEALTHCARE and iopamidol (ISOVUE) from BRACCO, both launched in 1985, represented a new generation. These agents offered improved safety profiles with lower osmolality and viscosity compared to older ionic agents, translating to reduced patient discomfort and fewer adverse events. Further refinements led to agents like ioversol (OPTIRAY), introduced by LIEBEL-FLARSHEIM in 1988, continuing the trend of enhanced tolerability and diagnostic efficacy. Individual radiographic contrast agents within the approved landscape are differentiated primarily by their iodine concentration, osmolality, viscosity, and specific indications for which they are optimized. For instance, the OMNIPAQUE line (iohexol) offers various concentrations (e.g., 140, 180, 300, 350) catering to different imaging needs, from myelography and CT cisternography to general CT imaging. Similarly, ISOVUE (iopamidol) and OPTIRAY (ioversol) provide a range of concentrations and formulations suitable for procedures like cerebral arteriography and peripheral arteriography. While efficacy in terms of image enhancement is generally high across modern agents, differences in viscosity and osmolality can influence ease of injection, patient comfort, and the potential for adverse reactions, particularly in vulnerable patient groups. Today, Radiographic Contrast Agents are foundational in diagnostic imaging, often serving as first-line agents for a wide array of procedures. The market is mature, with originator brands like OMNIPAQUE and ISOVUE still widely used, alongside generic and biosimilar versions of key compounds, though specific biosimilar entrants and years are not detailed in the provided data. The standard of care involves selecting an agent based on the imaging modality, the specific anatomical region being examined, and the patient's clinical status, including renal function and history of prior reactions. While generally safe, class-wide considerations include the risk of contrast-induced nephropathy and hypersensitivity reactions, necessitating careful patient selection and monitoring.
+13 more (biosimilars and reformulations not shown). ★ = originator.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.